Where did you go to the peak pharmacy to benefit your life?
Release time:
2022-12-13
Recently, many people passing by on the street of the west city found that the signboard of Yishou Shenxing Pharmacy of Jianfeng Pharmacy was missing. This time-honored store, which has been operating in Xishi Street for more than 20 years and has a long history, suddenly can't be seen, which makes people a little unaccustomed. Many people speculate that Yishou Shenhang is redecorating? Is it not done? With the same question, the reporter interviewed Xu Junxiong, general manager of Jianfeng Pharmacy.
Is Yishou Shengxing closed?
Xu Junxiong: No, I just moved to Luojiatang. Yishou Shenhang Pharmacy moved from Xishi Street to No. 13 22 Changda Street, Luojiatang Community, Xinshi Street in December of 2022 . The new store has already started trial operation and is scheduled to hold opening activities from 12 24 to 26 . welcome all new and old customers. Why do you want to move?
Xu Junxiong: The move is out of consideration of market planning and store layout. Xishi Street is a golden business district, and it is relatively close to Jinhua Central Hospital. The surrounding area is a popular location for pharmacies. There are a large number of pharmacies here, the distance between the stores is not far, the coverage is overlapping, and the competition is fierce. Only the stores of Jianfeng Pharmacy sometimes include Zhen Ge Store, Xinhua Street Store, Tianfutang Store, etc. Among them, Xishi Street is less than
400meters from the flagship store Shi Zhen Ge. After considering the adjustment of store layout, location, store rent increase and other factors, Jianfeng Pharmacy decided to focus on the development of Shizhen Pavilion in this area and move Yishou to participate in the trip. Why did you move to Luojiatang?
Xu Junxiong: The location of the drugstore was changed to serve customers better and serve more customers. There are many schools and residential areas around Luojiatang, with large flow of people, which is suitable for pharmacy operation. In the past, the location and main business volume of the peak pharmacy were mostly concentrated in the city center of Wucheng District. In the future, it is planned to expand to the periphery of the city center, and finally form a pattern of spreading all over the city and covering counties and cities. No matter where it expands, the idea of serving the people wholeheartedly will not change.
(Reporter
Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page